Felicia Cao, MD
Enriched profileAssistant Professor · University of North Carolina Hospitals
Felicia Cao is Assistant Professor at University of North Carolina Hospitals. OpenAlex indexes 23 publications with 247 citations (h-index 8); ClinicalTrials.gov lists 1 registered study with this person as an investigator.
Data verified 3 Nov 2026
Overview
Updated 3 Nov 2026
Felicia Cao, MD, PHD, is Assistant Professor at University of North Carolina Hospitals. The public record shows 23 publications with 247 citations (h-index 8), centered on CAR-T cell therapy research, Immunotherapy and Immune Responses, Immunodeficiency and Autoimmune Disorders. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 3 companies.
- Most recent indexed publication: 2025 · Open forum infectious diseases
- Top research focus: CAR-T cell therapy research
- 1 registered trials on ClinicalTrials.gov
- Open Payments reporting from 3 companies
Generated from the cited public record · current as of 3 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 2 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 8.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 3 Nov 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
- Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
Sponsor: UNC Lineberger Comprehensive Cancer Center
Industry payments
Updated 3 Nov 2026
3 companies reported payments to CMS in program years 2025–2025. These are public disclosures, not judgments. The latest:
- BeOne Medicines USA, Inc.Program year20251 payment
- Janssen Scientific Affairs, LLCProgram year20251 payment
- Legend Biotech USA Inc.Program year20251 payment
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
70.7%ACE inhibitor43.9%Lisinopril100%Part D<11 patientsAldosterone antagonist (MRA)26.8%Spironolactone100%Part D<11 patientsHormonal (systemic)
29.3%l-Thyroxine29.3%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 3 Nov 2026
3 congress contributions (2012–2025) across AACR, ASH per OpenAlex. The most recent:
- Rehabilitation needs and clinical associations post CAR T-cell therapy: A retrospective analysis
ASH Annual Meeting
ASH2025Co-author - Female Gender Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplant
ASH Annual Meeting
ASH2020Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 3 Nov 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults.
Open forum infectious diseases
Article2025
Most-cited works
by citation count (OpenAlex)- 01Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of GliomaArticle122 citations2018
- 02Engineering oncolytic vaccinia virus to redirect macrophages to tumor cellsArticle21 citations2020
- 03Generalized metabolic bone disease and fracture risk in Rothmund-Thomson syndromeArticle17 citations2017
- 04
- 05
Network
Updated 3 Nov 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 3 Nov 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Henry Lesesne, MD
University of North Carolina Hospitals
Brianna Frame, MD
University of North Carolina Hospitals
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles